Tag Archives: Venture Capital

Investing in Truemed

Andreessen Horowitz

Today, the United States is the sickest country in the developed world.

We spend more per capita on healthcare than any other nation, but 90 percent of those dollars are spent managing chronic conditions after people get sick. Something is not working.

Health isn’t created in a doctor’s office. Going to the doctor after you’ve already developed diabetes, heart disease, kidney disease, cancer or another chronic condition is like going to the mechanic after you’ve totaled a car. It’s the right thing to do – but wouldn’t it be better to avert the crash in the first place?

Truemed’s mission is to do just that: to shift more of our healthcare dollars toward True Medicine – exercise, good sleep, supplements, movement: the things that prevent disease, as opposed to just treating them once they’re sick.

When we met Truemed’s cofounder & CEO Justin Mares, we were compelled by his articulation of this extremely important mission to make preventive, health-creating behaviors accessible at scale. He explained how if our “great American sickening” continues, it will end the American experiment. It is impossible to have a healthy society made up of sick humans. His decade of experience as a successful serial founder building in health and nutrition has given him a rare clarity of vision, one that ultimately led him to build Truemed. There are few founders better suited to bring this vision to life.

We couldn’t be more proud to be partnering with Justin and leading the company’s $34 million Series A.

How does it work? 

Truemed is premised on the idea that people should be prescribed healthy lifestyle interventions long before they need to be prescribed drugs.

Today, Truemed enables consumers to use tax-advantaged HSA and FSA funds on evidence-based lifestyle interventions. It does so with a simple option at checkout that prompts consumers to complete a telehealth intake form. A licensed provider reviews this information (alongside clinical research about the intervention) to determine if the product is a recommended intervention for the individual’s condition. If so, the provider can decide to write a unique Letter of Medical Necessity (LMN), which can unlock HSA/FSA spending on effective lifestyle interventions. For many consumers, they average 30 percent savings by using pre-tax funds.

The company already powers HSA/FSA payment acceptance for more than 3,000 merchant partners, including Peloton, Eight Sleep, Rogue Fitness, Garmin, Barry’s, Momentous, CrossFit, Athletic Greens, and many more.

This is just the beginning. Truemed is reimagining a future where prevention becomes the default setting of American health, where people can invest in the habits and tools that prevent disease long before they enter the medical system. We’re thrilled to partner with Justin and the Truemed team as they build toward a system that redirects the flow of U.S. healthcare spending from managing illness to creating health.

Join the mission – check out Truemed and explore careers at the company.

Categories: News

Tags:

Graphite + Cursor: One Engineering Platform for the AI Era

Accel

Today Graphite is joining forces with Cursor to build the ultimate engineering platform for the AI era.

When we first partnered with Merrill, Tomas, and Greg, we saw a massive opportunity to re-imagine code collaboration, starting with review. Code review’s core primitives had not been re-thought for decades, and the pressure on this “outer loop” was made obvious as AI increased code volume tenfold. Graphite was tackling these problems head-on with infrastructure that supported the fastest-moving engineering organizations at scale.

Similarly, our conviction in Cursor came from the belief that owning the core flywheel of code generation would be the richest source of intent and context for downstream workflows. We believed this “inner loop” would continue to compound, evolving from a mere text editor to an AI-native operating system engineers would live in every day.

Graphite + Cursor: One Engineering Platform for the AI Era

Fast forward to today, and these theses have converged. Code generation and review are rapidly blending together, and collaboration is becoming fluid across teams of humans and agents.

The refrain we now hear from engineering leaders is simple: the “inner loop” and “outer loop” should be connected.The ultimate software engineering platform will combine the raw horsepower of code generation with the reliability, contextual understanding, and collaboration of a code review platform. This combination is exactly what Graphite and Cursor make possible together.

From our time working with both teams, we see a lot of shared DNA: distinctive product taste, exceptional talent density across New York and San Francisco, and a relentless commitment to building tools developers absolutely love. Together, these qualities form a uniquely powerful foundation that is hard to replicate, and even harder to beat.

Congratulations to the entire Graphite team on this milestone. We couldn’t be more excited to continue to partner and build the platform to define engineering in the years to come.

written by

Christine Esserman

Categories: News

Tags:

CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries

5Am Ventures

Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases

CAMP4 to receive $17.5 million upfront and eligible for additional milestone-based payments, in addition to tiered royalties

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, has entered into a strategic research, collaboration and license agreement with GSK to identify and develop antisense oligonucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications.

“Protein under-expression plays a critical role in diseases such as neurodegenerative and kidney disease. Our collaboration with GSK, focused on the rapid identification of novel targets and potential ASO therapeutics that increase the expression of validated genetic targets, underscores the potential of our discovery platform to create transformational medicines for patients,” said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4.

Under the terms of the agreement, CAMP4 will receive a $17.5 million cash upfront payment. Additionally, CAMP4 has the potential to receive additional payments for certain development and commercial milestones, in addition to tiered royalties on future product sales.

CAMP4 will utilize its proprietary RAP Platform® to identify regRNAs controlling the expression of multiple gene targets and generate regRNA-targeting ASO candidates that amplify target gene expression for potential development. GSK will be responsible for the further development and commercialization of ASO drug candidates identified through the collaboration.

Chris Austin, SVP Research Technologies, GSK, said: “We are excited to collaborate with CAMP4, combining their RNA discovery platform to increase specific gene activity with GSK’s expertise in therapeutic oligonucleotides, genetics and advanced laboratory and data technologies. This agreement aims to drive the development of novel medicines for neurodegenerative and kidney disease and demonstrates our approach of harnessing cutting-edge technologies to deliver transformational therapies for patients.”

About CAMP4 Therapeutics 
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.

Forward-Looking Statements 
This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning the development of ASO drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications; the potential of the Company’s platform technology; the Company’s receipt of future contingent milestones and/or royalties; and the Company’s strategy, goals, business plans and focus. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of product candidates, which is complex, and the risk that third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for current and future product; the Company’s reliance on third parties to conduct preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of suppliers; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as well as other information the Company files with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contacts

Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com

Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com

Categories: News

Tags:

Empowering the Future of Energy: How exnaton is Leading Europe’s Electrification Shift

Elevator Ventures

Our portfolio company exnaton is driving electrification across Europe.

As Europe accelerates toward full-scale electrification, utilities are under increasing pressure to modernize their systems, launch innovative energy products, and meet rapidly evolving customer expectations. The rise of electric vehicles, rooftop solar and decentralized flexibility is transforming the energy market from a linear value chain into a dynamic ecosystem – one that demands smarter billing, transparent data andregulatory compliance at unprecedented scale.

Regulatory requirements are amplifying this shift. The EU Electricity Market Design law (Directive EU/2024/1711) has been transposed into national law, reshaping how Member States enable flexibility, consumer participation and dynamic pricing. This policy is underpinned by the continent-wide rollout of smart meters: Spain has reached 100% coverage, the Netherlands is above 95%, France is at 93%, and Austria has already surpassed roughly 95% of its meters by late 2024. Germany is targeting 95% by 2030 and Poland is moving toward 100% by 2031.

Utilities know change is unavoidable, and most recognize the challenge of moving fast enough in this new environment of electrification, flexibility and data-driven regulation.

This is where exnaton comes in.

A Real-World Challenge: Utilities Need Flexibility, not full IT Overhauls

Most utilities operate on legacy ERP systems built for a world of stable, predictable electricity flows. But dynamic tariffs, prosumer models, energy communities and smart electric vehicle charging require a more innovative approach to analyzing data coming from PoDs (Point of Delivery). The in-house development of capabilities, such as automated billing and seamless customer interfaces, is slow, expensive and often impractical.

Customers, meanwhile, increasingly expect transparency and personalization. Regulators demand accuracy and flexibility. Markets reward innovation.

exnaton bridges this gap with a modern intelligence layer that transforms existing infrastructure – without forcing utilities to rebuild it.

About exnaton: An Intelligence Platform Built for the New Energy System

Founded in Zurich in 2020, exnaton develops an AI-powered SaaS platform that helps utilities deploy next-generation energy products rapidly and at scale. Rather than replacing existing IT architecture, exnaton adds a modular, flexible intelligence layer that handles billingworkflows, dynamic pricing and data analysis.

Today, more than 50 utilities across Europe rely on exnaton’s technology – including examples such as TotalEnergies in Belgium, the E.ON brands eprimo, Bayernwerk in Germany, enersuisse in Switzerland, and Burgenland Energie in Austria – collectively demonstrating how exnaton enables both large multinational suppliers and regional champions to drive the digital transformation of the energy sector.

With research backgrounds from ETH Zürich, Stanford University, and University of St. Gallen, the team combines academic depth with practical industry expertise. Their mission is simple: empower utilities to deliver sustainable, data-driven energy products that make the energy transition tangible for every household.

Deep Dive: How the Platform Works – and why it matters

exnaton’s intelligence platform focuses onthree key areas that address the most pressing needs of today’s utilities:

AI-Enhanced Billing

Utilities can automate complex billing processes using granular, 15-minute energy data from smart meters. AI-powered processing ensures accuracy, reduces operational costs and minimizes manual reconciliation work – critical for dynamic tariffs and flexible grid fees.

Modular & Scalable Architecture

The platform integrates directly with existing ERP systems, enabling faster time-to-market for new, time-series-based energy products. Its modularity supports a wide range of use cases, from energy communities and peer-to-peer sharing to intelligent electric vehicle charging and prosumer billing.

White-Label Customer Experience

exnaton provides a customizable user interface that allows consumers to easily monitor their energy consumption, production and – where integrated – smart device activity. This transparency empowers customers to make data-driven decisions – and increases their engagement with sustainable products.

For utilities, this combination improves efficiency, unlocks new business models, and strengthens customer loyalty. For consumers, it makes the energy transition intuitive, accessible, and actionable.

Why Energy Tech: The “Beyond Banking” Trend

For Elevator Ventures, this is a crucial investment that aligns perfectly with our focus on “Beyond Banking” solutions in relevant areas like energy transition. The energy market represents a huge opportunity, particularly given Raiffeisen’s existing activities in the Austrian energy sector like Auri by Raiffeisenlandesbank Niederösterreich-Wien, Enlion and Raiffeisen Regenerative as well as the strong network of clients and partners in energy utilities across Austria and Central and Eastern Europe. As we see it, exnaton can play a leading role in the integration of finance into the future of energy.

Looking Ahead: Scaling Europe’s Decarbonized Grid

With its newly raised Series A financing, exnaton is poised to accelerate its European expansion and further develop AI-driven capabilities for real-time billing and decentralized and data-driven flexibility management.

Join us in Powering the Future

At Elevator Ventures, we believe in elevating the growth of founders who are building the infrastructure for tomorrow. By supporting exnaton, we are backing a team that is redefining how utilities innovate – and is ultimately accelerating the transition to a cleaner, smarterand more flexible energy system.

Learn more about exnaton: https://www.exnaton.ai/

picture of the exnaton software on phones

Categories: News

Tags:

Chai Discovery Announces $130 Million Series B To Transform Molecular Discovery

No Comments
Oak HC FT

Chai Discovery, the AI company that predicts and reprograms the interactions between biochemical molecules, today announced its $130 million Series B financing round co-led by Oak HC/FT and General Catalyst. This round of financing values the company at $1.3 billion.

The news comes on the heels of Chai’s most recent announcement, where the company showed their latest models can now design molecules with important “developability” properties and tackle “hard-to-drug” targets that have historically been challenging for traditional techniques.

The round also comes just months after Chai Discovery announced a $70 million Series A and revealed Chai 2, the first zero-shot generative platform that achieves double digit experimental success rates in de novo antibody design – a 100-fold improvement over previous computational methods.

“We’re standing on the precipice of a new era for the biopharmaceutical industry,” said Josh Meier, co-founder and CEO of Chai Discovery. “We’re in awe of the rate of progress on the models – what looked like five-year problems just months ago are now getting solved in weeks. Our latest models can design molecules that have properties we’d want from actual drugs, and tackle challenging targets that have been out of reach. These models will unleash a new wave of first-in-class and best-in-class therapeutics, and the early adopters in pharma will be the big winners.”

The fundraise was co-led by Oak HC/FT and General Catalyst, with participation from Thrive Capital, OpenAI, Dimension, Menlo Ventures, Lachy Groom, Yosemite, Neo, and SV Angel. New investors Emerson Collective and Glade Brook also joined the round.

“We believe biology is becoming programmable, rewiring what was once an empirical art into an engineered discipline,” said Elena Viboch, Managing Director at General Catalyst. “Chai’s team is leading this transformation – advancing the technical frontier and expanding what’s possible in therapeutics.”

By converting what has traditionally been a lengthy iteration cycle into a computational process, Chai can materially compress the time to first-in-human studies, tackle hard to drug and “undruggable” targets, and accelerate the overall time to commercialization.

“Nowhere is AI transformation more needed than in drug development – the process is slow, expensive, and imprecise,” said Annie Lamont, Co-Founder & Managing Partner at Oak HC/FT. “It can take over a decade and cost upwards of a billion dollars to bring a medicine from bench to bedside. The Chai Discovery team is rewriting that story, fusing world-class AI and biological expertise to dramatically accelerate how medicines are discovered. We’re thrilled to support them as they push the boundaries of what’s possible in this field.”

The company will use the funding to accelerate research and product development, and expand commercialization efforts as they continue to execute on the vision of building a “computer-aided design suite” for molecules.

The Series B round brings Chai’s total funding to more than $225 million. As part of the fundraise, Annie Lamont from Oak HC/FT and Hemant Taneja from General Catalyst will be joining the board.

For more information on Chai Discovery and its platform, visit https://www.chaidiscovery.com.

About Chai Discovery

Chai Discovery builds frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules, the fundamental building blocks of life. Its mission is to transform biology from science into engineering. The team hails from pioneering research and applied AI companies such as OpenAI, Meta FAIR, Stripe, and Google X, and is backed by top investors including OpenAI, Thrive Capital, Menlo Ventures, and Dimension.

About Oak HC/FT

Oak HC/FT is a venture and growth equity firm specializing in investments in fintech and healthcare. Using partnership as a foundation, Oak HC/FT guides companies and founders at every stage, from seed to growth, to create businesses that make a measurable and lasting impact. Founded in 2014, Oak HC/FT has invested in more than 100 portfolio companies and has over $5.3 billion in assets under management. Oak HC/FT is headquartered in Stamford, CT, with an office in San Francisco, CA. Follow Oak HC/FT on LinkedIn and X and learn more at https://www.oakhcft.com/.

About General Catalyst

General Catalyst is a global investment and transformation company that partners with the world’s most ambitious entrepreneurs to drive resilience and applied AI.

We support founders with a long-term view who challenge the status quo, partnering with them from seed to growth stage and beyond.

With offices in the U.S., Europe, and India, we have supported the growth of 800+ businesses, including Airbnb, Anduril, Anthropic, Applied Intuition, Commure, Glean, Gusto, Helsing, Hubspot, Kayak, Livongo, Mistral, Ramp, Samsara, Snap, Stripe, Sword, and Zepto.

For more: www.generalcatalyst.com, @generalcatalyst

Categories: News

Tags:

From Plans to Progress: Announcing the 8VC-Bobyard Partnership

8VC

We’re proud to announce our support of Bobyard: as lead investors in their $35mm Series A and as partners pursuing an American building renaissance.

The building trades turn design into reality, are integral to our civilization, and remain vastly underserved by technology. The chart below tells the story: US labor productivity has nearly tripled since 1950, while construction has flatlined, and then declined. This creates a natural win-win opportunity: the trades need modern tools, and Silicon Valley needs meaningful, real-world missions.

‍Bobyard addresses a defining challenge of construction: adding intelligence to plans and drawings in order to build faster. This requires pushing the state of the art forward – clever applications of existing AI aren’t enough. Bobyard is a deep talent bet, conducting foundational computer vision research and solving problems not well-articulated in literature today.

Specifically, Bobyard brings previously unheard-of speed and accuracy to takeoff (calculating material, labor, and equipment quantities from project plans) and estimation (using those quantities to assign costs and create project bids). Drawings are the source of truth for every project, but they’re inconsistent & non-standard, hard to interpret, and prone to errors that compound as they pass from GCs to subs.

Conventional takeoff + estimation requires headcount, and takes hours, often days, to complete. For smaller firms, this means stretched employees juggling too many hats; for larger ones, it caps bid volume and growth. Bobyard resets the timeline by optimizing for what modern AI does best (counting materials; extracting structured information; synthesizing data into decisions) and what humans do best (coordinating with subs and GCs; high-end labor; customer relationships).

Bobyard’s first focus is commercial landscaping, one of the toughest trades for takeoff and estimation. These drawings are dense and non-standard: planting sheets can include thousands of shrubs across dozens of species, with arbitrary symbols that vary from project to project. Estimators have traditionally placed color-coded dots on each item by hand, tracing polygons for sod, mulch, and pavers, measuring irrigation lines, and plugging it all into spreadsheets.

Bobyard replaces that workflow entirely. Contractors upload a PDF, select a legend, run analysis, and receive takeoff quantities in seconds. Under the hood, the platform runs dozens of proprietary computer vision models simultaneously—symbol counting, linear measurement, area detection, text parsing—each built from scratch and optimized for construction drawings. First-run accuracy exceeds 95%+ and automates 90%+ of the task, with fast inference times. Results are displayed visually for instant review, editing, or adjustment, keeping users in control.

The platform also handles the full estimation workflow: material costs, labor, customizable templates, and flexible export formats. Historical costs, vendor quotes, and completed assemblies are stored and organized for easy querying, replacing the paper-chasing that’s long defined document management in the trades.

The results speak for themselves: Bobyard customers see a 50–70% reduction in takeoff time, submit 5x more bids per estimator, and unlock an average of $1.1 million in additional revenue per employee annually.

Customers like Chopper Landscaping project manager/estimator John Barrett immediately see fewer mistakes, more accurate quantities, and more consistent margins. These advantages add up quickly, helping contractors win more bids, prevent costly change orders, and increase revenue an average of 27%, with no additional headcount.

Bobyard has scaled to hundreds of customers, with thousands more in sight. Contractors stay because the product automates their most tedious work, slashes errors, and frees them to spend time where it matters: onsite and with clients. Superusers log 30+ hours a week on the platform, and Bobyard has become their core workspace.

From landscaping, Bobyard will expand to framing, mechanical, electrical, plumbing, drywall, and more. The playbook mirrors Bedrock, another 8VC investment: win the hardest problem first, then use that technical and operational edge to scale across verticals. Each new trade is a greenfield opportunity, and a chance to compound network effects between subs and GCs.

At 8VC, we’ve long believed that building well is a moral responsibility. “The world is broken. Let’s fix it” is both a practical and aesthetic commitment: elevated spaces and elevated ideals are inseparable. As people who’ve built homes, offices, and a university, we’ve wanted a platform like Bobyard for years. Early in the AI wave, we explored building something ourselves, but CV capabilities weren’t ready, and we hadn’t yet found the right leader.

Then we met Michael Ding: a mathematician, scholar of history, and one of the youngest students to complete Stanford’s advanced AI coursework. He obsesses over details that conceal enormous value, and he’s assembled a team of CV PhDs, top-tier engineers, and high-performing salespeople that rivals the best AI companies.

This funding will allow Michael and the Bobyard team to advance their models, deepen landscaping capabilities, and expand into new trades. What’s needed now is talent to match these ambitions. If you’re passionate about solving hard problems at the intersection of AI and the physical world, Bobyard is hiring in engineering, sales, and customer success. And if you’re a contractor ready to transform how you bid and build, you can see it for yourself.

By mastering the critical stages between design and dirt, Bobyard is helping to reverse a 70-year productivity decline, and proving that the trades and technology can move forward together.

Categories: News

Tags:

Orq.ai Closes €5M in Seed Funding to Help Enterprises Deploy AI Agents at Scale

Curiosity VC

Our portfolio company Orq.ai, a generative AI collaboration startup built for companies to model, deploy, and manage enterprise-grade AI applications, has raised €5 million in an oversubscribed seed funding round led by seed + speed Ventures and Galion.exe, with continued backing from Curiosity and other existing investors Spacetime, XO Ventures, xdeck ventures, Waves Capital, and GoldenEggCheck. The round brings Orq.ai’s total funding to €7.3 million.

The investment marks a strong vote of confidence in Orq.ai’s mission to help enterprises build and deploy AI agents efficiently, maintain control over workflows and data, and scale across any infrastructure. With the launch of its new Agent Studio, Orq.ai now enables businesses to design agents in their own way, configuring behaviors, workflows, and decision rules while the platform handles the entire execution layer. Orq.ai already supports forward-thinking organizations across Europe and the US, including Afas, Moneybird Keyrus, and Helloprint, as they move from isolated experiments to operational AI systems running at scale.

With the new capital, Orq.ai will expand its 25-person team across engineering, enterprise sales, and customer success, while deepening its presence in key European markets and accelerating its North American growth.  The round also introduces new strategic angels and advisors such as  Sam Bourton, co-founder of QuantumBlack/McKinsey, Adriaan Mol, founder of Mollie, and Daniel Gebler, CTO of Picnic, who will support Orq.ai’s expansion into more advanced enterprise and data governance capabilities.

“Enterprises are no longer experimenting with AI for curiosity. They want to implement it fast, but most of them are stuck passing real systems into production. We believe Orq.ai is the solution for their needs, as it for us. it accelerates our development process daily and is even used by non-technical profiles. Orq.ai’s unified agent lifecycle platform shortens iteration time, reduces friction and brings stability to deploy agents at scale.” says Kevin Kuipers, Founding Partner of Galion.exe.

“AI agents are becoming a foundational layer of enterprise and B2B software, much like cloud infrastructure in the last technology cycle. Companies will need a reliable way to orchestrate, govern, and scale these agents across operations, and Orq.ai is building the platform that will enable that shift.“ says Alexander Kölpin, Managing Director, seed + speed Ventures.

The investment comes at a pivotal moment for enterprise AI.  Despite growing interest, many companies remain stuck at the prototype stage due to fragmented tools and the lack of governance needed to operate AI reliably in production, a gap Orq.ai directly addresses. “Most companies can build a great demo. The real challenge is getting that demo into production without losing control over quality, compliance, or costs,” said Sohrab Hosseini, Co-founder of Orq.ai. “Orq.ai exists to close that gap.”

Once AI systems encounter real-world data, regulatory obligations, and operational complexity, performance and control often break down. Orq.ai provides a full enterprise control layer to manage, secure, and scale AI systems across teams and environments. It is the only platform that combines experimentation, evaluation, observability, AI gateway, governance, and agent runtime into a single environment.

“Leading enterprises have moved past AI experimentation. Their focus now is production,” said Herman Kienhuis from early investor Curiosity VC. “Orq.ai supports that transition by reducing iteration time, cutting operational friction, and giving engineering teams a stable foundation for scaling agents.”

With stricter requirements under the EU AI Act, GDPR, and broader data governance rules, European companies increasingly need AI systems that can run securely within their own infrastructure. Orq.ai’s infrastructure-agnostic design, spanning cloud, hybrid, and fully on-prem deployments, provides a practical path to meeting sovereignty and residency needs. US organizations benefit from the same flexibility, allowing easier integration with existing architectures and compliance frameworks.

Orq.ai’s unified platform includes an AI gateway with access to more than 300 models, built-in evaluation and monitoring, knowledge-base integration, and collaboration tools that reduce agent development time by 67% and free more than 10% of engineering capacity.

The funding coincides with a full rebrand and redesigned platform experience, reflecting Orq.ai’s evolution from a developer-focused tool into a comprehensive enterprise solution trusted across industries. More than 100 organizations now rely on Orq.ai as they operationalize AI at scale.

About Orq.ai
‍Founded in 2022 and headquartered in Amsterdam, Orq.ai is the enterprise control platform for the full AI agent lifecycle. The company’s Platform 4.0 enables organizations to experiment, evaluate, deploy, observe, and optimize AI agents through a unified interface that prioritizes safety, collaboration, and scalability. Orq.ai supports over 300+ LLM models and offers flexible deployment options, including cloud, hybrid, and on-premises configurations, to meet enterprise data sovereignty requirements. The company serves forward-thinking enterprises and AI-native startups across Europe and the United States. For more information, visit orq.ai.

Categories: News

Tags:

Fusable leverages Reltio’s real-time intelligence capabilities to revolutionize its customer data solutions.

.406 Ventures

reltio seo image

Redwood Shores, CA and Charlotte, NC — December 1, 2025 — Reltio®, a leader in real-time data intelligence, and Fusable, a leader in data-driven solutions for the trucking, agriculture, and construction industries, today announced their collaboration using Reltio Data Cloud to deliver enhanced functionality to Fusable’s customers as well as improved internal efficiencies.

Fusable’s decision to select Reltio was the result of a vigorous evaluation process, centered on a thorough review of business requirements and a successful proof of concept (POC). A key factor that stood out was the Reltio POC team’s expertise, which provided exceptional detail and helped Fusable translate its requirements into actionable solutions. The POC successfully validated Reltio’s ability to ingest and manage data from multiple sources, ensure data quality and governance, manage complex company hierarchies, and enable real-time data synchronization.

“Our search for a unified, trusted data solution was driven by two needs–to improve the efficiency of our data management and to provide an enhanced experience for our customers,” said Matthew Cox, Chief Data Officer at Fusable. Our data landscape spans complex and diverse sources, making data unification across fragmented datasets challenging and resource-intensive. With Reltio’s capabilities, we can now deliver a unified, seamless view of our data—creating a powerful competitive advantage for our customers.”

Since going live, Fusable has achieved its goal of gaining a unified view of its product data—a significant milestone. The implementation automatically clusters records from multiple distinct sources, revealing new business opportunities through cross-source data. The consolidation has had an immediate impact on data quality, drastically reducing the manual stewardship workload.

Reltio’s unified data capabilities are central to Fusable’s long-term strategy, empowering it to deliver a single, trusted view of data across all products. This unified foundation will fuel the next generation of Fusable solutions—from prospecting and market intelligence to risk assessment and performance management. In the near term, Fusable is expanding Reltio mastering to include internal corporate data and developing a robust data governance framework, with Reltio serving as the core platform for our data stewards.

“We were pleased to collaborate with Fusable on their quest to tap into the tremendous power of their data using our innovative platform, which helps them build trust and get the most value from this unified data,” said Ansh Kanwar, Chief Product Officer at Reltio. “Organizations across all industries rely on data from myriad sources tracking information about their customers, suppliers, geographic markets, regulatory compliance and much more. The need for accurate, real-time insights generated from unified data will become even more critical as organizations continue to embrace agentic AI to better serve their customers.”

“Reltio” is a registered trademark, and “Reltio AgentFlow” and “Reltio Data Cloud” are each trademarks of Reltio, Inc. All Rights Reserved.

About Fusable

Fusable is a leading provider of data-driven solutions for industrial and infrastructure markets and the financial services ecosystem that supports them. Focused on innovation and customer-centricity, Fusable leverages extensive datasets to help businesses understand markets, drive sales and manage risk. Fusable is known for its flagship brands, including EDA, Iron Solutions, Central Analysis Bureau, RigDig BI, Price Digests, and EquipmentWatch. Discover more at fusable.com.

Contact

Reltio
Mary Ellen Higgins
781.789.1911
maryellen@satuitgroup.com

Fusable
Michelle Reyes
321-805-1607
michellereyes@fusable.com

Categories: News

Tags:

FamilyWell Health Announces $8M Series A Funding to Accelerate Nationwide Expansion of Integrated Women’s Mental Health Care

.406 Ventures

Building on its success in maternal mental health, funding will accelerate FamilyWell’s growth into menopause care, advance its AI-enabled digital platform, and scale the FamilyWell Academy provider training programs

 

BOSTON, Nov. 18, 2025 (GLOBE NEWSWIRE) — FamilyWell Health, the leading integrated women’s mental health company, today announced the closing of $8 million in Series A financing led by New Markets Venture Partners, with participation from existing and new investors – .406 Ventures, GreyMatter Capital, The Alix Foundation, The Donna Fund, and The Lee Foundation. This funding will accelerate FamilyWell’s national expansion, bringing its proven maternal mental health model to health systems, clinics, and payers across the country. It will also advance the company’s AI capabilities to broaden access, drive growth into perimenopause and menopause care, and scale its provider training programs through the FamilyWell Academy.

Women’s mental health remains one of healthcare’s most underserved and fastest-growing areas of need:

Founded in 2022 by Dr. Jessica Gaulton, a practicing physician at Harvard and survivor of postpartum depression, FamilyWell embeds virtual women’s mental health services—care coordination, coaching, therapy, and psychiatry—directly into clinics and health systems. Patients are connected to care within 24 hours and supported by a specialized team of providers. Through its integrated perinatal mental health program, 1 in 4 pregnant patients are referred to FamilyWell, with 95% of patients experiencing clinical improvement by four months. In addition, the model alleviates provider burden, while enabling clinics to capture untapped revenue from payers directly.

FamilyWell currently operates in Massachusetts, New Hampshire, Connecticut, Illinois, and Texas covering over 200,000 lives nationwide. The company has also recently partnered with one of the country’s largest managed care organizations, expanding access to insurance-covered coaching, therapy, and psychiatry for more women and birthing people across the country.

“FamilyWell is an ideal fit for New Markets’ mission to invest in evidence-based solutions that improve lives and expand access to life-saving care,” said Mark Grovic, General Partner and Founder, New Markets Venture Partners. “By integrating proven women’s mental health care into everyday clinical workflows, FamilyWell reduces suffering, strengthens family well-being, and helps parents return to work and thrive.”

Expansion Into Perimenopause and Menopause
Today, more than 50 million U.S. women are in perimenopause and up to 70% experience mental health symptoms such as anxiety, depression, insomnia, and cognitive changes. To meet the strong demand from its OB/GYN partners, FamilyWell has extended its integrated care model to support women through perimenopause and menopause. With this expansion, FamilyWell now supports women throughout the reproductive lifecycle, from fertility through menopause.

“What FamilyWell has built is more than a product—it’s a movement toward the care women and families deserve,” said Dr. Neel Shah, MD, MPP, Chief Medical Officer, Maven Clinic and Board Member, FamilyWell Health. “By embedding mental health care directly into the OB/GYN clinic, FamilyWell is scaling empathy as effectively as technology. Their proven model meaningfully improves patient outcomes—helping women reclaim their well-being and dignity during some of life’s most challenging transitions.”

Learn more about FamilyWell’s menopause offering:
https://www.familywellhealth.com/perimenopause

FamilyWell Academy
The FamilyWell Academy is training the next generation of women’s mental health providers to meet the nation’s growing need for specialized, reproductive mental health care. The company’s Perinatal Behavioral Health and Peri-/Menopause Behavioral Health certification programs equip coaches with the skills to deliver evidence-based, compassionate care—and help close the provider workforce gap.

“The mental health needs of women have been overlooked for far too long,” said Dr. Jessica Gaulton, founder and CEO of FamilyWell Health. “This capital enables us to expand our integrated care model, accelerate AI innovation, and deepen collaborations that make timely, high-quality support possible. Through the FamilyWell Academy and together with our OB/GYN partners, we’re reshaping the standard of care and addressing one of the most critical health crises facing women today.”

About FamilyWell Health
FamilyWell Health is transforming women’s mental health across the reproductive journey, from fertility through menopause and beyond. We embed evidence-based, insurance-covered mental health care directly into women’s health practices and health systems. By seamlessly integrating a virtual team of care managers, coaches, therapists, and psychiatric providers into clinical workflows, FamilyWell is improving patient outcomes and reducing medical provider workloads. Through the FamilyWell Academy, we are educating the next generation of women’s mental health providers to solve the growing workforce gap. Learn more at familywellhealth.com and follow us on LinkedIn and Instagram.

Media Contact:

press@familywellhealth.com

Categories: News

Tags:

Gabrielle Union Joins Nema Health as Investor & Strategic Advisor

.406 Ventures

At Nema, our mission has always been deeply personal. My cofounders and I started the company to bring people the kind of support I needed after I experienced trauma – and so far, we’ve walked hand-in-hand with thousands of people across the country, helping them heal from their PTSD and find the peace they deserve.

Today, we’re deeply honored to share a new step toward achieving our mission: actress, producer, and best-selling author Gabrielle Union has joined Nema as both an investor and advisor. Her voice — powerful, raw, and always real — brings tremendous strength to our mission of helping survivors heal.

Gabrielle (or “Gab,” as our team has quickly come to know her) has spent decades speaking publicly and powerfully about the trauma she endured following her sexual assault at age 19. In the years since, she has become an extraordinary advocate for survivors, using her platform to shine light on the pain and realities of PTSD — and to call out the unacceptable prevalence of sexual violence among women and queer people.

Most of the Nema community knows how deep the roots of trauma run in our country: an estimated 80% of Americans will endure a trauma and 30 million will go on to develop PTSD. Marked by debilitating symptoms like hypervigilance, intrusive thoughts & flashbacks, social avoidance, negative mood, and heightened anxiety, survivors often struggle to believe that recovery from PTSD is possible at all.

Gab’s decision to invest and advise affirms something we deeply believe at Nema: healing after trauma is not just possible – it’s something we’re wholeheartedly committed to and have ample hope for for each and every one of our patients.

“I’ve worried over the years that I’ll never get better,” Gab shared. “I’ve lived with this shadow for so many years, and sometimes, when I think I’m out of the woods, it comes sneaking up on me again. I now know that’s because I never found the right treatment that endures in the long-term. Now that I’m undergoing treatment with Nema, I’m seeing many of the beliefs about my trauma that have gripped me start to fade away. I know it’s not my fault anymore, but it is my responsibility to take back my life. I owe that to myself.”

At Nema, our patients access treatment from research-backed therapies like Cognitive Processing Therapy; support from clinicians and survivors including therapists, psychiatrists, and peer mentors working in concert to guide healing; and the knowledge that 95% of our patients report noticeable improvement in their PTSD symptoms after our program.

Gab’s joining marks a pivotal moment for Nema. As we continue expanding into new states and health plans, Gab’s relationship with Nema means the stories, struggles, and courage of trauma survivors are seen and validated every day. We are so honored to have such a vulnerable and brave advisor on board to help us deliver on our mission.

“To those living with the kind of trauma that feels like it could sink you – I see you,” Gab added. “I know what it feels like. You are strong, you are capable, you can find peace. There is so much love for you in the world, and you deserve every last ounce of it.”

As the first order of business for our partnership, Nema and Gab teamed up to create our Trauma Survivor Guide, a free resource for anyone struggling in the aftermath of trauma. In it, you’ll find help understanding PTSD, how symptoms show up, resources for finding treatment, and exercises to help you heal. You can visit the Guide here.

Categories: People

Tags: